KRISHGEN has successfully developed and achieved CE certification for its Biomonitoring Kits for Therapeutic Mabs. This enables the kits to be marked as IVD. These include ELISA kits for Rituximab, Adalimumab, Trastuzumab, Eculizumab, Cetuximab amongst others.
The uniqueness of these kits is the high degree of validation including correlation to the innovator / reference drugs available in the market. Each assay for measurement of the dr
BIOSYSTEMS, today announced that, it has successfully developed the first
commercial testing kit for detection of Nipah Virus based on the ELISA
platform. The three kits can be used to detected the Nipah virus antigen and
the IgG / IgM antibodies.
Dr Jayaraman D. Lead Scientist, leading CRO company
I have been working with a team from KRISHGEN on an assay development and customization before giving us. The project was complicated and needed technical expertise in immunology as we were working on an insulin analog. I was very pleased with their technical competence and also mastering immunology and delivering a tough project to us on time. Their rigor, punctuality and expertise have been a recipe for the high standards, I would expect for such project from them. Kudos, Krishgen Team!!!
Mr Ramesh Sravanan, VP-Supply Chain
The expertise and command on the logistics chain including the regulatory
guidelines from Krishgen is something we admire. As they often indicate, let us
do the supplies, and let your team focus on science … is really something the
company works on. Delivering consistently, with less than 1% error or delay
consistently is the key to their success.
Dr Keith Stevens, visiting Scientist, Norfolk University, UK
To have a company understand science and work with them, is a pleasure. Krishgen
not only sells but understands what it sells in terms of the complex cutting
Mellisa Karlowski, Lead Researcher, east coast US CRO
The company is good on understanding its customers, is transparent and
speaks science. This makes it easier for us to work with them.